Entrada Therapeutics, Inc. (TRDA)
- Previous Close
12.43 - Open
12.23 - Bid 12.27 x 100
- Ask 12.38 x 100
- Day's Range
11.91 - 12.58 - 52 Week Range
10.62 - 18.44 - Volume
78,637 - Avg. Volume
77,908 - Market Cap (intraday)
415.31M - Beta (5Y Monthly) -0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.20 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
www.entradatx.comRecent News: TRDA
Performance Overview: TRDA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRDA
Valuation Measures
Market Cap
415.31M
Enterprise Value
131.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.17
Price/Book (mrq)
1.71
Enterprise Value/Revenue
1.02
Enterprise Value/EBITDA
-409.88
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.18%
Return on Assets (ttm)
-0.55%
Return on Equity (ttm)
-2.94%
Revenue (ttm)
129.01M
Net Income Avi to Common (ttm)
-6.68M
Diluted EPS (ttm)
-0.20
Balance Sheet and Cash Flow
Total Cash (mrq)
351.97M
Total Debt/Equity (mrq)
28.15%
Levered Free Cash Flow (ttm)
149.04M
Research Analysis: TRDA
Company Insights: TRDA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: TRDA
Daily – Vickers Top Buyers & Sellers for 03/27/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/22/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.